---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-002907"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:50:19.628106+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025

## Summary
- Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.
- Full-year 2024 revenue now ~$64.3M (29% YoY growth) vs prior $68-70M.
- FY 2025 revenue guidance $100-106M (55-65% growth).
- Cashflow breakeven and GAAP profitability now expected in Q4 2025, delayed from Q3 2025.
- Miss attributed to slower hospital year-end purchasing; new products RECELL GO and Cohealyx remain growth drivers.

## SEC filing metadata
- accession: 0000950170-25-002907
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017025002907/0000950170-25-002907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017025002907/rcel-20250107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-002907
- JSON: https://secwatch.observer/filing/0000950170-25-002907.json
- Plain text: https://secwatch.observer/filing/0000950170-25-002907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.